GLP-1 Research Peptides: Single, Dual, and Triple Agonists Compared
A research overview of the GLP-1 receptor agonist class — from single-receptor analogs to dual GIP/GLP-1 and triple-agonist compounds — and how each is studied in metabolic-pathway research.
For in-vitro and laboratory research only. None of the compounds described below are FDA-approved for the contexts discussed; published research is preclinical or limited-stage clinical literature summarized for educational purposes.
Incretin-receptor research has become one of the most active areas in metabolic peptide science. The compounds fall into three structural generations — single agonist, dual agonist, and triple agonist — each engaging an expanding set of receptors. This article maps the landscape and points to which research-supply formats correspond to each.
The receptor families involved
- GLP-1R — glucagon-like peptide-1 receptor; involved in insulin secretion, satiety signaling, and gastric emptying.
- GIPR — glucose-dependent insulinotropic polypeptide receptor; involved in postprandial insulin response and adipocyte metabolism.
- GCGR — glucagon receptor; involved in hepatic glucose output and energy expenditure.
Single GLP-1 agonists
The first generation of incretin research peptides targets only GLP-1R. PH-SM1 10mg is a research-grade GLP-1 receptor agonist commonly used in incretin-pathway studies. Published preclinical work focuses on insulin-secretion kinetics, glucose tolerance models, and central-satiety signaling.
Dual GIP/GLP-1 agonists
Dual agonists engage GIPR and GLP-1R simultaneously. PH-TZ2 10mg belongs to this class. Preclinical literature has reported additive effects on insulin response and on adipose-tissue glucose handling relative to GLP-1-only agonists, with the GIPR arm contributing the larger share of the body-composition signal in rodent studies.
Triple agonists (GLP-1 / GIP / GCG)
Triple agonists add glucagon-receptor engagement. PH-RT3 5mg, 10mg, 20mg, and higher-dose variants up to 60mg are research-supply formats for this class. Adding GCGR engagement contributes to energy-expenditure effects observed in rodent metabolic models, on top of the incretin-driven insulin and satiety signals.
The amylin angle
Cagrilintide 5mg is not a GLP-1 family member but is frequently studied alongside it. It is a long-acting amylin-receptor agonist; published preclinical and early clinical literature has explored amylin/GLP-1 co-administration for compounded satiety signaling.
Research handling notes
All of these peptides ship lyophilized and follow standard peptide storage practice — see our peptide storage guide. Triple agonists with larger sequences and bulkier modifications can be more sensitive to freeze-thaw cycles; aliquot reconstituted material before freezing.
What to verify on the COA
Because the GLP-1 class includes molecules with very similar names (and very different sequences), COA sequence verification is non-negotiable. See how to read a peptide COA for the fields that matter.
Reminder: The information above is a literature summary for in-vitro and laboratory research. Products are not intended for human use.